文献速递肝病

定量宏基因组学评估肝硬化患者肠道微生物组改变:与慢加急性肝衰竭及预后的关系

Alterations in Gut Microbiome in Cirrhosis as Assessed by Quantitative Metagenomics: Relationship With Acute-on-Chronic Liver Failure and Prognosis.
PubMed 文献 · Gastroenterology · 2020-09-14

研究前瞻性收集182例肝硬化患者粪便样本,用定量宏基因组学分析肠道微生物组,涵盖代偿期、无ACLF的急性失代偿期及ACLF全疾病谱,并以健康人作对照。肝硬化患者基因和宏基因组物种丰富度显著降低,ACLF患者改变最明显,微生物组改变与肝硬化并发症及3个月生存相关,并可预测3个月生存。

要点

  • 肝硬化患者肠道微生物组基因和物种丰富度较健康人显著降低,且随疾病分期加重。
  • ACLF患者肠道肠球菌和消化链球菌属显著增加,部分原籍菌减少。
  • 肠道微生物组改变与肝性脑病、感染等并发症及3个月生存相关。

核心结论

  • 肝硬化以肠道微生物组显著改变为特征,改变程度与疾病分期平行,ACLF时变化最大。
  • 改变的肠道微生物组与肝硬化并发症和生存相关,可能参与疾病进展和不良预后。
  • 这些结果需在未來研究中进一步证实。

研究设计与样本

  • 前瞻性收集182例肝硬化患者粪便样本,涵盖代偿期、无ACLF的急性失代偿期和ACLF,并以一组健康人作对照。
  • 使用Ion Proton测序仪(ThermoFisher Scientific)构建DNA文库并测序。
  • 将微生物基因分组为簇,称为宏基因组物种。

主要发现

  • 与健康人相比,肝硬化患者基因和宏基因组物种丰富度显著降低,此丰富度丢失与疾病分期相关,在ACLF患者中尤为明显,且校正抗生素治疗后仍持续存在。
  • ACLF与肠球菌和消化链球菌属显著增加及部分原籍菌减少相关。
  • 肠道微生物组改变与终末期肝病模型评分和Child-Pugh评分及器官衰竭相关,并与部分并发症(尤其肝性脑病和感染)相关。
  • 肠道微生物组可预测3个月生存,且预测因子稳定。
  • 功能分析显示肝硬化患者富集乙醇生成、γ-氨基丁酸代谢和内毒素生物合成等相关通路。

局限性

  • 原文结论指出这些结果应在未来研究中进一步证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Cirrhosis is associated with changes in gut microbiome composition. Although acute-on-chronic liver failure (ACLF) is the most severe clinical stage of cirrhosis, there is lack of information about gut microbiome alterations in ACLF using quantitative metagenomics. We investigated the gut microbiome in patients with cirrhosis encompassing the whole spectrum of disease (compensated, acutely decompensated without ACLF, and ACLF). A group of healthy subjects was used as control subjects. METHODS: Stool samples were collected prospectively in 182 patients with cirrhosis. DNA library construction and sequencing were performed using the Ion Proton Sequencer (ThermoFisher Scientific, Waltham, MA). Microbial genes were grouped into clusters, denoted as metagenomic species. RESULTS: Cirrhosis was associated with a remarkable reduction in gene and metagenomic species richness compared with healthy subjects. This loss of richness correlated with disease stages and was particularly marked in patients with ACLF and persisted after adjustment for antibiotic therapy. ACLF was associated with a significant increase of Enterococcus and Peptostreptococcus sp and a reduction of some autochthonous bacteria. Gut microbiome alterations correlated with model for end-stage liver disease and Child-Pugh scores and organ failure and was associated with some complications, particularly hepatic encephalopathy and infections. Interestingly, gut microbiome predicted 3-month survival with good stable predictors. Functional analysis showed that patients with cirrhosis had enriched pathways related to ethanol production, γ-aminobutyric acid metabolism, and endotoxin biosynthesis, among others. CONCLUSIONS: Cirrhosis is characterized by marked alterations in gut microbiome that parallel disease stages with maximal changes in ACLF. Altered gut microbiome was associated with complications of cirrhosis and survival. Gut microbiome may contribute to disease progression and poor prognosis. These results should be confirmed in future studies.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Solé C, Guilly S, Da Silva K, et al. Alterations in Gut Microbiome in Cirrhosis as Assessed by Quantitative Metagenomics: Relationship With Acute-on-Chronic Liver Failure and Prognosis. Gastroenterology. 2020. PMID: 32941879. doi:10.1053/j.gastro.2020.08.054

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。